Steven Rosenberg to receive 2024 AACR Award for Lifetime Achievement in Cancer Research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Steven A. Rosenberg, fellow of the AACR Academy, was named the recipient of the 2024 AACR Award for Lifetime Achievement in Cancer Research. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


The phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival for the first-line treatment of patients with human epidermal growth factor receptor 2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.